Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2666605 in Advanced Solid Tumors
NCT04809805Phase 1Terminated
- Sponsor
- Bayer
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAY2666605 in melanoma, glioblastoma (GBM), anaplastic astrocytoma (AA) and 5 more (2 arms), sponsored by Bayer. Primary endpoints: Incidence and severity of Treatment-Emergent Adverse Events including TESAEs, Incidence of Dose Limiting Toxicities and 5 more. Started Apr 2021; status: terminated.
02
Drugs
BAY2666605
03
Conditions
melanomaglioblastoma (GBM)anaplastic astrocytoma (AA)sarcomaepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04809805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809805.